Trial Profile
A Phase I Study of IRX4204 in Combination With Erlotinib in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs IRX 4204 (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Io Therapeutics
- 29 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 29 Mar 2022 Planned primary completion date changed from 1 Jul 2021 to 1 Jul 2023.
- 29 Mar 2022 Status changed from recruiting to suspended.